Health Care·Pharmaceuticals·$547.6B
Johnson & Johnson (JNJ) is a leading healthcare company that develops pharmaceuticals, medical devices, and consumer health products. With a market cap of $556 billion, it plays a crucial role in the health sector, especially in pharmaceuticals, where it focuses on innovative treatments and therapies.
Earnings Per Share (EPS)
EPS is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
Revenue figures provide insight into the company's sales performance and overall growth.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+3.82%
Avg Stock Reaction
+1.22%
In Q1 2026, Johnson & Johnson reported an EPS of $2.70, slightly beating expectations. The company did not provide revenue figures, leaving some uncertainty about overall performance.
Management Promises & Guidance
Analysts expect Johnson & Johnson to report solid earnings this quarter, with a consensus EPS of $2.84. Investors are particularly focused on how the company is managing its pharmaceutical pipeline and market challenges.
Bull Case
If JNJ exceeds EPS expectations and shows strong revenue growth, it could indicate robust demand for its products, leading to positive investor sentiment.
Bear Case
Conversely, if the company fails to meet EPS expectations or shows signs of declining sales, it could raise concerns about its growth prospects and lead to a negative market reaction.
Earnings Per Share (EPS)
$2.84EPS is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$25.0BRevenue figures provide insight into the company's sales performance and overall growth.
The print will turn on these two things.
Q1
Will the EPS exceed $2.84?
A beat on EPS could signal strong operational performance and investor confidence in the company's growth.
Q2
What is the revenue outlook for the pharmaceutical segment?
Given the importance of pharmaceuticals to JNJ's overall business, guidance on revenue trends will be closely scrutinized.
Why consensus could be wrong
The consensus may underestimate JNJ's ability to leverage its pharmaceutical pipeline, especially in emerging markets where demand is growing.
Supporting Evidence
Recent product launches have shown strong initial sales, suggesting potential upside in revenue forecasts.
The company's historical performance indicates a pattern of beating EPS estimates, which may not be fully reflected in current expectations.
Key Risk
If JNJ's pharmaceutical revenue exceeds $15B, it could invalidate bearish sentiment and shift market perceptions.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether JNJ can maintain its growth trajectory amidst market challenges.
Bull Confirmed If
An EPS of $2.90 or higher would confirm strong demand and operational efficiency.
Bear Confirmed If
An EPS below $2.70 would raise concerns about profitability and growth.
Implied Move
±5%
Historical Avg
±1.9%
The options market is pricing in a potential move of 5% in either direction following the earnings report, indicating uncertainty among investors.
Options are pricing ±5.0% while JNJ has averaged ±1.9% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If JNJ beats expectations, history suggests a potential average one-day move of +4.1%, confirming strong operational performance.
In-Line / Cautious
If results are in line with expectations, the market may react cautiously, leading to muted stock movement as investors await further guidance.
Miss
Should JNJ miss expectations, history indicates an average one-day move of -0.7%, which could trigger concerns about the company's growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GOLDMAN SACHS GROUP
Jul 14, 2026